Nucleoside analogues for chronic hepatitis B: Antiviral efficacy and viral resistance

American Journal of Gastroenterology

Volumn 97, Issue 7, 2002, Pages 1618-1628

  Papatheodoridis, George V ^a   Dimou, Evangelini ^a   Papadimitropoulos, Vasilios ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ADENOSINE DERIVATIVE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; GANCICLOVIR; GUANOSINE DERIVATIVE; LAMIVUDINE; NUCLEOSIDE ANALOG; PENCICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; HEPATITIS B; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0036314982     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04175-8     Document Type: Review

References (125)

1. Hepatitis B: Global importance and need for control
2. Hepatitis B virus infection
3. Chronic hepatitis B
4. Chronic type B hepatitis and the "healthy" HBsAg carrier state
5. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
6. Natural-history and prognostic factors for chronic hepatitis type B
7. The major etiology of hepatocellular carcinoma
8. The treatment of chronic viral hepatitis
9. Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
10. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
11. Diagnosis and management of pre-core mutant chronic hepatitis B
12. Interferon-alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B
13. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B
14. Adverse events associated with interferon-alfa therapy in patients with chronic viral hepatitis
15. Lamivudine. A review of its therapeutic potential in chronic hepatitis B
16. Hepatitis B infection: Pathogenesis and management
17. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men
18. Profound suppression of hepatitis B virus replication with lamivudine
19. Pharmacokinetics, absolute biovailability, and absorption characteristics of lamivudine
20. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
21. Analysis of the earliest steps of hepadnaviral replication: Genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity
22. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate
23. Novel mechanism for reverse transcription in hepatitis B virus
24. Hepadnaviral envelope proteins regulate amplification of covalently closed circular DNA
25. Secreted hepatitis B surface antigen polypeptides are derived from a transmembrane precursor
26. Mutational analysis of the hepatitis B virus P gene product: Domain structure and RNAse H activity
27. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus
28. Computer analysis of retroviral pol genes: Assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes
29. Rapid in vitro selection of human immunodefficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
30. Antiviral chemotherapy for the treatment of hepatitis B virus infections
31. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine
32. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues
33. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase, and mammalian DNA polymerases alpha, beta, and gamma
34. Viral dynamics in hepatitis B virus infection
35. Formation of the pool of covalently closed circular viral DNA in hepadna virus-infected cells
36. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
37. A one-year trial of lamivudine for chronic hepatitis B
38. Lamivudine as initial treatment for chronic hepatitis B in the United States
39. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
40. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
41. Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B
42. Incremental increases in HBeAg seroconversion and continued ALT normalisation in Asian chronic HBV (CHB) patients treated with lamivudine for four years
43. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea
44. Durable HBeAg response in Chinese patients treated with lamivudine
45. Three year lamivudine therapy in chronic HBV
46. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
47. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B
48. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
49. Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B
50. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
51. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
52. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B
53. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
54. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin
55. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis
56. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
57. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis
58. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
59. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B
60. Famciclovir treatment of anti-HBe+ chronic hepatitis B: Results of a randomized, placebo-controlled study
61. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation
62. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation
63. Famciclovir treatment of decompensated HBV cirrhosis
64. Ganciclovir
65. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients
66. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation
67. Oral ganciclovir treatment in chronic hepatitis B virus infection: A pilot study
68. Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: A randomized study
69. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir
70. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy in HIV-infected adults: A randomised, double-blind, placebo-controlled trial
71. Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B infection
72. Adefovir dipivoxil suppresses lamivudine resistant hepatitis B virus in liver transplant recipients
73. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
74. A study of oral entecavir given for 28 days in both treatment-naive and pre-treatment subjects with chronic hepatitis
75. Effectiveness of a low dose of entecavir in treating recurrent viremia in chronic hepatitis B
76. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks
77. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues
78. Antiviral activity of 48 weeks of emtricitabine (FTC) treatment in patients with HBeAg negative/HBV DNA positive chronic hepatitis B (CHB)
79. A randomized, double-blind, comparison of 3 doses of emtricitabine (FTC) in patients with chronic hepatitis B (CHB) given 48 weeks of treatment (FTCB-102)
80. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy
81. The clinical significance of surface antigen variants of hepatitis B virus
82. Immunopathogenesis and natural course of anti-HBe-positive chronic hepatitis with replicating B virus
83. Mechanism of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription
84. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers
85. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea
86. Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species
87. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation
88. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
89. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
90. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
91. Long-term therapy of chronic hepatitis B with lamivudine
92. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
93. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy
94. 20-Fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw
95. Selection of mutations in the hepatitis B virus polymerase during therapy of transplanted recipients with lamivudine
96. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine (-)-beta-L-2′,3′-dideoxy-3′-thiacytidine) in vitro
97. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
98. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase gene
99. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
100. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy
101. Influence of B domain mutation (L528M) of the hepatitis B virus polymerase on replication ability and resistance to nucleoside analogues
102. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
103. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
104. HBV reactivation and biochemical breakthroughs after initially effective lamivudine therapy in patients with precore mutant HBV related liver disease
105. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
106. Long term lamivudine treatment in anti-HBe positive chronic hepatitis B: An interim analysis
107. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease
108. Risk factors selection of YMDD mutants, their consequences in liver transplant recipients, ranging from sudden onset of liver failure to no disease
109. Hepatic decompensation associated with lamivudine: A case report and review of lamivudine-induced hepatotoxicity
110. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy
111. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
112. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss
113. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure
114. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
115. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy
116. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
117. Comparison of anti-HBV activity of adefovir against different lamivudine-resistant HBV strains in vitro and in liver transplant patients
118. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
119. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine - Preliminary 24 week results
120. Safety and efficacy of adefovir dipivoxil for the treatment of lamivudine resistant HBV in patients post liver transplantation
121. Genotypic and phenotypic analysis of HBV isolated from patients exposed to adefovir dipivoxil for up to 36 weeks
122. Week 48 resistance surveillance in chronic hepatitis B patients enrolled in a phase III clinical study of adefovir dipivoxil
123. Resistance monitoring in chronic hepatitis B patients exposed to adefovir dipivoxil for 72 to 136 weeks
124. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy
125. Chronic hepatitis B